Treeline Biosciences, a Massachusetts-based biotech startup, has revealed details of its pipeline including three cancer drug candidates entering clinical testing. The company has raised over $1.1 billion from investors like Arch Venture Partners, OrbiMed, and GV since its founding in 2021. Treeline’s programs include a protein degrader targeting BCL6 in lymphoma, a pan-KRAS inhibitor for solid tumors, and a licensed EZH2 inhibitor from Jiangsu Hengrui Pharmaceuticals. This substantial funding and diversified oncology pipeline signal a long-term, ambitious development strategy deviating from traditional milestone financing models.